
Pediatric Rheumatologist

No OPD information available
Juvenile Idiopathic Arthritis (JIA)
Arthritis
Osteomyelitis
Osteomyelitis in Children
Bursitis
Chronic Recurrent Multifocal Osteomyelitis
Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss Syndrome)
Infantile Neutropenia
Intussusception in Children
Kawasaki Disease
Psoriasis
Psoriatic Arthritis
SAPHO Syndrome
Sialadenitis
Vasculitis
Jonathan D. Akikusa is a male doctor who helps kids with different health problems like arthritis, bone infections, and other conditions. He has special skills in treating these issues, like Juvenile Idiopathic Arthritis and Kawasaki Disease.
Dr. Akikusa talks to his patients in a way that makes them feel comfortable and safe. Patients trust him because he listens to their concerns and explains things clearly. He cares about making sure they get better.
To keep up with the newest medical info, Dr. Akikusa reads studies and goes to conferences. This helps him give the best care to his patients. He also works well with other doctors and healthcare workers to make sure everyone is on the same page.
Dr. Akikusa's work has helped many kids feel better and live healthier lives. For example, his research on chronic bone infections in children has improved how these conditions are diagnosed and treated. He also led a study on a new medicine for Juvenile Idiopathic Arthritis, which has helped many young patients.
One of Dr. Akikusa's important publications is about classifying bone infections in children. This study helps doctors understand these conditions better, so they can treat kids more effectively. He has also been part of a clinical trial testing a new treatment for Juvenile Idiopathic Arthritis, which has given hope to many families.
In summary, Dr. Jonathan D. Akikusa is a caring and knowledgeable doctor who works hard to help kids with bone and joint problems. His dedication to his patients and his contributions to medical research have made a positive impact on many young lives.
Enrollment Status: Completed
Published: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
